

Amphetamines (D/L Differentiation), Urine

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	6/8/1981
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

D-Amphetamine	None Det ng/mL		
D-Amphetamme	Urine		
	Reporting Limit: 10 ng/mL		
	Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)		
L-Amphetamine	None Det ng/mL		
	Urine Reporting Limit: 10 ng/mL		
	Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)		
D-Amphetamine Percent	0.0 % Urine		
	Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)		
L-Amphetamine Percent	0.0 %		
	Urine Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)		
D-Methamphetamine	None Det ng/mL		
	Urine Reporting Limit: 10 ng/mL		
	Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)		

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:



L-Methamphetamine	None Det ng/mL Urine Reporting Limit: 10 ng/mL Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)
D-Methamphetamine Percent	0.0 % Urine D-methamphetamine at more than 20% of the total is considered indicative of a source other than an over-the-counter (OTC) product. A greater than 20% concentration of the D-isomer can result from illicit methamphetamine use, or D-methamphetamine-containing prescription drugs, or from the metabolism of certain prescribed drugs (e.g., benzphetamine) Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)
L-Methamphetamine Percent	0.0 % Urine Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration. Testing performed at NMS Labs, Inc. 200 welsh Road Horsham, PA 19044-2208 CLIA 39D0197898

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:



VERIFIED/REPORTED DATES					
Procedure	Accession	Collected	Received	Verified/Reported	
D-Amphetamine	23-171-402825	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
L-Amphetamine	23-171-402825	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
D-Amphetamine Percent	23-171-402825	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
L-Amphetamine Percent	23-171-402825	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
D-Methamphetamine	23-171-402825	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
L-Methamphetamine	23-171-402825	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
D-Methamphetamine Percent	23-171-402825	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
L-Methamphetamine Percent	23-171-402825	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Sati Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 23-171-402825 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 3 of 3 | Printed: 12/27/2023 1:35:37 PM 4848